Moleculin Biotech Inc. (NASDAQ:MBRX) has announced the submission of requests to regulatory authorities in Poland for approval for the opening of two more sites for its ongoing Phase 1/2 annamycin study in treating acute myeloid leukemia.
Moleculin to get two new clinical sites for Annamycin study in Poland
Walter Klemp, the CEO and Chairman of Moleculin, indicated that they were delighted to continue with the Annamycin trials despite the challenges posed by the coronavirus pandemic. The CEO indicated that they were adding two more hospitals in Poland, one in Kielce and another in Szczecin, as they move to expedite trial participation. Kemp added that once the requests are approved in time, they expect the sites to commence enrolment of participants in Q3.
Currently, the company has five clinical sites conducting Annamycin acute myeloid leukemia clinical trials across Europe. Once approved, the Kielce and Szczecin site will bring the total number of sites to seven.
Moleculin commences enrolment in Emory University WP10-66 study
The company has also announced that it has commenced enrolment in the Emory University first phase WP1066 clinical trials for brain tumor treatment in children. Already the first patient has been enrolled in the study that will be carried at the Atlanta Aflac Cancer and Blood Disorders Centre of Children’s Healthcare.
WP1066 is Moleculin’s lead molecule in its portfolio of transcription immune modulators and simulators. Already the molecule has demonstrated in animal models that it can stimulate a natural immune response. It can inhibit the activated STAT3 gene transcription factor, which is normally the tumor-associated activity master regulator.
Moleculin’s CEO indicated that the STAT3 gene transcription factor has, for long, seemed to be an “undruggable target.” Klemp said that they had demonstrated activity with WP1220 in patients, which is among the molecules in the portfolio. He affirmed that the study represents the company with a chance to demonstrate that the STAT3 gene transcription factor is a viable target. The CEO added that Moleculin was delighted to be part of the effort seeking to develop a treatment for brain tumors in children.
